Use of Diabetes Drug Actos linked to Bladder Cancer and Heart Failure

Actos (generic name: pioglitazone hydrochloride) is an oral medication that is used to treat type 2 diabetes. It is manufactured by Takeda and sold under the brand name Actos , Actoplus Met®, and Duetact®. The use of Actos has been associated with bladder cancer as well as cardiac problems such as heart failure. Actos is in the same class of diabetic drugs as Avandia and in 2007 the FDA determined that the labels for these drugs should contain a black box warning informing the public of the risk of heart failure. A black box warning is the strongest warning that the FDA can request a drug manufacturer to make.

The FDA has now issued a warning that the use of Actos may also be linked to bladder cancer. In July of 2011 the governments of France and Germany suspended all sales of Actos in these countries. On 8/4/11 the FDA issued a safety bulletin informing the public and health care workers that they have approved a new label for the drug that would warn of the risk of bladder cancer to patients who use Actos for over a year. This new safety warning is based on the FDA’s review of data from ten year epidemiological study.

If you have taken Actos , Actoplus Met®, or Duetact® and have been diagnosed with bladder cancer or suffered heart failure we can help you. The lawyers at Devereaux, Stokes, Fernandez & Leonard have experience in going up against large corporations and getting compensation for their clients when big companies put their profits ahead of public safety. If you or a loved one has taken Actos and suffered from heart failure or bladder cancer contact us for a free consultation.

Contact us for a free consultation